The Indian Health Service, Tribal and Urban Indian immunization programs report on the immunization status of American Indian and Alaska Native (AI/AN) children 3-27 months of age, 19 – 35 months of age, Adolescents 13 – 17 years of age and Adults. They also report on influenza vaccine coverage for all age groups. These reports are submitted to the IHS Division of Epidemiology and Disease Prevention on a quarterly basis.

**3-27 Month Old Report**

The 3 – 27 month report is designed to help programs ensure timely vaccination and identify children who may be falling behind so they can be brought up to date. The criteria listed below are used to monitor coverage in the following age groups:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Vaccines</th>
<th>Age Group</th>
<th>Vaccines</th>
</tr>
</thead>
</table>
| 3-4 months | • DTAP1  
• IPV 1  
• Hib 1  
• Hepatitis B 1  
• PCV1  
• (ROTA1)†  | 16-18 months | • DTAP 3  
• IPV 2  
• MMR 1  
• Hib 2/3  
• Hepatitis B 2  
• Varicella  
• PCV3  
• (ROTA3)†  |
| 5-6 Months | • DTAP 2  
• IPV 2  
• Hib 2  
• Hepatitis B 2  
• PCV2  
• (ROTA2)†  | 19-23 months | • DTAP 4  
• IPV 3  
• MMR 1  
• Hib 3/4  
• Hepatitis B 3  
• Varicella  
• PCV4  
• (ROTA3)†  |
| 7-15 months | • DTAP 3  
• IPV 2  
• Hib 2  
• Hepatitis B 2  
• PCV3  
• (ROTA3)†  | 24-27 months | • DTAP 4  
• IPV 3  
• MMR 1  
• Hib 3/4  
• Hepatitis B 3  
• Varicella  
• PCV4  
• (ROTA3)†  
• (Hepatitis A1)†  |

† Not included in Age appropriate immunization coverage calculations

Rotavirus vaccine (ROTA) and hepatitis A, though recommended, are not included in overall age appropriate coverage calculations. Data on ROTA and hepatitis A vaccine coverage are reported where available.
For FY19 Q3, 12 IHS Areas submitted immunization reports from IHS, Tribal, and Urban Indian health centers (I/T/U). This composite report provides information on the immunization status of 22,141 children 3-27 months old. Of these, 14,357 or 64.8% received all age-appropriate vaccinations compared to 63.9% (14,909/23,350) of children 3-27 months in the 2nd Quarter of FY19 [Figure 1].

**Figure 1**

Age Appropriate Immunization Coverage  
3-27 Month Olds  
FY04 Q1 – FY19 Q3, IHS National
Two Year Old Report

The two year old report (children 19-35 months old) is used to monitor progress towards the GPRA childhood immunization indicator.

Starting in 2011, the vaccines series measure used to monitor coverage in this age group is, the 4:3:1:3*:3:1:4 (4 DTaP, 3 IPV, 1 MMR, the full series of Hib (3 or 4 doses, depending on product type of vaccine), 3 Hep B, 1 VAR, 4 PCV) series. The HP 2020 goal is 80% with the 4:3:1:3*:3:1:4 series, and 90% coverage with each individual vaccine in the series.

4:3:1:3*:3:1:4 Series
In FY19 Q3, 12 IHS Areas completed reports. Overall 65.8% (10,907/16,568) of two year olds had completed the 4:3:1:3*:3:1:4 vaccine series compared to 66.6% (11,473/17,221) in FY19 Q2.

Figure 2

4:3:3*:3:1:4 Coverage
2 Year Old
FY09 Q1 – FY 19 Q3, IHS National

4:3:1:3*:3:1:4 series includes 4 doses of DTaP, 3 doses of Polio (IPV), 1 dose of MMR, the full series of Hib (3 or 4 doses, depending on product type of vaccine), 3 doses of Hep B, 1 dose of Varicella and 4 doses of PCV
Adolescent Report

This report collects data on adolescents 13 – 17 years who meet the “Active Clinical User” definition (e.g. 2 visits in the last 3 years) and is designed to monitor uptake of recommended adolescent vaccines (e.g. tetanus toxoid, reduced diphtheria toxoid and acellular pertussis [Tdap], meningococcal conjugate [MCV4], and human papillomavirus [HPV] vaccines) and monitor coverage in the adolescent population with the following recommended childhood vaccines: 1 dose of Td or Tdap, 3 doses of hepatitis B, 2 doses of MMR, and 2 doses of Varicella/Hx of chickenpox. A summary of immunization coverage for 13 year olds and 13 –17 year olds with these vaccines is included below.

Immunization Coverage for 13 year olds

For FY19 Q3, the 12 IHS Areas combined reported on 13,325 thirteen year olds compared to 13,908 thirteen year olds in the FY19 Q2 report.

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>IHS All Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose of Tdap</td>
<td>89.9% (11,979/13,325)</td>
<td>78% - 93%</td>
</tr>
<tr>
<td>1 dose of MCV4</td>
<td>87.5% (11,650/13,325)</td>
<td>71% - 93%</td>
</tr>
<tr>
<td>1 dose of HPV</td>
<td>80.8% (10,763/13,325)</td>
<td>58% - 94%</td>
</tr>
</tbody>
</table>

For FY19 Q3, 89.9% received 1 dose of Tdap vaccine, 87.5% had received 1 dose of MCV4 vaccine, and 80.8% received 1 dose of HPV [Figure 3].

Figure 3

Adolescent Vaccines Coverage
13 Year Old
FY10 Q4 – FY19 Q3, IHS National
Immunization Coverage for 13 – 17 year olds

For **FY19 Q3**, the 12 IHS Areas combined reported on 63,171 13–17 year olds compared to the FY19 Q2 report which included 65,013 13–17 year olds.

<table>
<thead>
<tr>
<th></th>
<th>IHS All Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 doses of Hepatitis B</td>
<td>96.2%</td>
<td>79% - 99%</td>
</tr>
<tr>
<td></td>
<td>(60,774/63,171)</td>
<td></td>
</tr>
<tr>
<td>2 doses of MMR vaccine</td>
<td>95.4%</td>
<td>78% - 99%</td>
</tr>
<tr>
<td></td>
<td>(60,265/63,171)</td>
<td></td>
</tr>
<tr>
<td>2 doses of Varicella vaccine or had a documented history of chickenpox</td>
<td>95.7%</td>
<td>75% - 99%</td>
</tr>
<tr>
<td></td>
<td>(60,463/63,171)</td>
<td></td>
</tr>
<tr>
<td>1 dose of Tdap vaccine</td>
<td>92.1%</td>
<td>75% - 99%</td>
</tr>
<tr>
<td></td>
<td>(58,149/63,171)</td>
<td></td>
</tr>
<tr>
<td>1 dose of MCV4 vaccine</td>
<td>90.6%</td>
<td>65% - 99%</td>
</tr>
<tr>
<td></td>
<td>(57,232/63,171)</td>
<td></td>
</tr>
<tr>
<td>1 dose of HPV vaccine</td>
<td>85.1%</td>
<td>60% - 99%</td>
</tr>
<tr>
<td></td>
<td>(53,792/63,171)</td>
<td></td>
</tr>
</tbody>
</table>

For **FY19 Q3**, 96.2% received 1 dose of Tdap vaccine, 90.6% had received 1 dose of MCV4 vaccine, and 85.1% received 1 dose of HPV vaccine [Figure 4].

**Figure 4**

*Adolescent Vaccines Coverage 13 – 17 Year Olds*  
*FY18 Q3 – FY19 Q3, IHS National*
HPV Coverage for 13 – 17 year olds

For FY19 Q3, the 12 IHS Areas combined reported on 63,049 13 – 17 years of age compared to FY19 Q2 which included 65,013 13-17 year olds. For FY19 Q3, 85.3% (53,792/63,049) had received 1 dose of HPV, 71.9% (45,366/63,049) had received 2 doses of HPV and 42.5% (26,832/63,049) had received 3 doses of HPV [Figure 5].

For FY19 Q3, coverage by Area ranged from 64% - 97% for HPV1, 50% - 91% for HPV2, and 28% – 63% for HPV3.

* NOTE: IHS implemented the 2-dose HPV schedule into the clinical decision support, however it is not reflected in the reports. Therefore, the HPV 2nd and 3rd dose coverage currently do not reflect the true coverage.

Figure 5

![HPV Coverage Graph]

*2-dose HPV recommendation. See note above.
The Adult Immunization Report was collected for the first time in FY12 Q4. This report collects data on patients meeting the “Active Clinical User” definition (e.g. 2 visits in the last 3 years) and reports vaccination rates for the following vaccines and age groups: Tdap in those 19 years+; HPV 1, 2 and 3 doses in Females 19-26 years; HPV 1, 2, and 3 doses in Males 19-21 years; Zoster vaccine in those 60 years+, and Pneumococcal polysaccharide vaccine at or after age 65 years.

For FY19 Q3 data was collected from all 11 IHS Areas on 429,398 active clinical patients 19 years and older compared to FY19 Q2 which included 436,959. Below is a chart with the coverage for each of the adult vaccines. Alaska Area has only one site on RPMS and did not report adult data, since the data would not be reflective of the area as a whole.

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>All IHS Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 dose of Tdap (19 years and older)</td>
<td>74.9% (321,800/429,398)</td>
<td>54% - 89%</td>
</tr>
<tr>
<td>1 dose of HPV females (19-26 years)</td>
<td>73.1% (29,221/39,975)</td>
<td>46% - 87%</td>
</tr>
<tr>
<td>3 doses of HPV females (19-26 years)</td>
<td>57.0% (22,783/39,975)</td>
<td>32% - 80%</td>
</tr>
<tr>
<td>1 dose of HPV males (19-21 years)</td>
<td>69.3% (7,207/10,407)</td>
<td>38% - 88%</td>
</tr>
<tr>
<td>3 dose of HPV males (19-21 years)</td>
<td>43.1% (4,481/10,407)</td>
<td>21% - 62%</td>
</tr>
<tr>
<td>1 dose of Zoster (60 years and older)</td>
<td>56.3% (56,056/99,597)</td>
<td>32% - 78%</td>
</tr>
<tr>
<td>1 dose of Pneumo (at/after 65 years)</td>
<td>77.8% (51,506/66,173)</td>
<td>51% - 86%</td>
</tr>
</tbody>
</table>

Figure 6

Adult Vaccines Coverage
FY18 Q3 – FY19 Q3, IHS National
Adult Composite Report

The Adult composite measure data is included in the Adult Immunization Report and is being collected for the first time in FY17 Q1. This report collects data on patients meeting the “Active Clinical User” definition (e.g. 2 visits in the last 3 years) and reports vaccination rates for the following vaccines and age groups: 19-59 years with Tdap ever and Tdap/Td <10 years; 60-64 years with Tdap ever and Tdap/Td <10 years and Zoster; 65+ years with Tdap ever and Tdap/Td <10 years and Zoster and Pneumo; and 19 years and older with appropriately vaccinated per age recommendation.

<table>
<thead>
<tr>
<th>Vaccines and Age Groups</th>
<th>All IHS Area Coverage</th>
<th>Range of Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tdap ever and Tdap/Td &lt; 10 years (19-59 years)</td>
<td>76.7% (251,932/328,488)</td>
<td>53% - 95%</td>
</tr>
<tr>
<td>Tdap ever and Tdap/Td &lt; 10 years (60-64 years)</td>
<td>31.9% (10,742/33,679)</td>
<td>14% - 88%</td>
</tr>
<tr>
<td>Tdap ever and Tdap/Td &lt; 10 years and Zoster and Pneumo (65 years and older)</td>
<td>58.9% (39,059/66,364)</td>
<td>27% - 91%</td>
</tr>
<tr>
<td>Appropriately vaccinated per age recommendation (19 years and older)</td>
<td>70.1% (300,993/429,398)</td>
<td>47% - 96%</td>
</tr>
</tbody>
</table>

Alaska Area did not report Adult data this quarter.

Figure 7

Adult Vaccine Composite Measures*
Appropriately Vaccinated Per Age Recommendations
FY18 Q3 – FY19 Q3, IHS National

* 19-59 years with Tdap ever and Tdap/Td <10 years; 60-64 years with Tdap ever and Tdap/Td <10 years and Zoster; 65+ years with Tdap ever and Tdap/Td <10 years and Zoster and Pneumo; and 19 years and older with appropriately vaccinated per age recommendation.